Next Article in Journal
The First Year Experience of Newborn Screening for Pompe Disease in California
Previous Article in Journal
Clinical Utility of Confirmatory Genetic Testing to Differentiate Sickle Cell Trait from Sickle-β+-Thalassemia by Newborn Screening
Open AccessReview

History of Newborn Screening for Cystic Fibrosis—The Early Years

1
University of Caen Normandy (UNICAEN), 14032 Caen, France
2
Caen University Hospital, 14040 Caen, France
3
East Anglian Biochemical Genetic Unit, Peterborough, UK
*
Author to whom correspondence should be addressed.
Int. J. Neonatal Screen. 2020, 6(1), 8; https://doi.org/10.3390/ijns6010008
Received: 20 December 2019 / Revised: 28 January 2020 / Accepted: 28 January 2020 / Published: 31 January 2020
This review summarises the trajectory of neonatal screening strategies for the detection of cystic fibrosis (CF) using the measurement of Immunoreactive Trypsin (IRT) in dried blood spots (DBS) from 1979 until the beginning of the 21st century when newborn screening (NBS) programmes started to spread throughout many countries, using IRT measurement combined with a CF genotype analysis of DBS.
Keywords: Newborn screening; Immunoreactive Trypsin(ogen); Dried Blood Spot; Radioimmunoassay; DNA Newborn screening; Immunoreactive Trypsin(ogen); Dried Blood Spot; Radioimmunoassay; DNA
MDPI and ACS Style

Travert, G.; Heeley, M.; Heeley, A. History of Newborn Screening for Cystic Fibrosis—The Early Years. Int. J. Neonatal Screen. 2020, 6, 8.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop